By Memorandum Opinion entered by The Honorable Gregory M. Sleet in Abbvie Inc. v. Hospira, Inc., C.A. No. 11-648- GMS (D.Del., October 24, 2014), the Court, following a two day bench trial and after having considered the entire record in the case and the applicable law, concluded that (1) the asserted claims of the patent-in-suit, U.S. Patent Number 6,136,799 (“the ‘799 patent”) are not invalid due to obviousness; and (2) Hospira’s proposed product does not infringe the ‘799 patent.

A copy of the Memorandum Opinion is attached.